July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Optical coherence tomography derived macular volume loss over 5 years in Stargardt disease
Author Affiliations & Notes
  • Fred Kuanfu Chen
    Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Western Australia, Australia
    Lions Eye Institute, Perth, Western Australia, Australia
  • Sukanya Arunachalam
    Lions Eye Institute, Perth, Western Australia, Australia
  • Natasha Vallis
    Lions Eye Institute, Perth, Western Australia, Australia
  • Di Huang
    Centre for Comparative Genomics, Murdoch University, Murdoch, Western Australia, Australia
    Lions Eye Institute, Perth, Western Australia, Australia
  • Yi Chen
    Lions Eye Institute, Perth, Western Australia, Australia
  • Jennifer A. Thompson
    Australian Inherited Retinal Disease Registry, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
  • Terri McLaren
    Australian Inherited Retinal Disease Registry, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
  • Tina Lamey
    Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Western Australia, Australia
    Australian Inherited Retinal Disease Registry, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
  • John De Roach
    Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Western Australia, Australia
    Australian Inherited Retinal Disease Registry, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
  • Samuel McLenachan
    Lions Eye Institute, Perth, Western Australia, Australia
  • Footnotes
    Commercial Relationships   Fred Chen, None; Sukanya Arunachalam, None; Natasha Vallis, None; Di Huang, None; Yi Chen, None; Jennifer Thompson, None; Terri McLaren, None; Tina Lamey, None; John De Roach, None; Samuel McLenachan, None
  • Footnotes
    Support  NHMRC grants 1142962 and 1116360, Telethon-Perth Children's Hospital Research Fund, Macular Disease Foundation Australia
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4521. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Fred Kuanfu Chen, Sukanya Arunachalam, Natasha Vallis, Di Huang, Yi Chen, Jennifer A. Thompson, Terri McLaren, Tina Lamey, John De Roach, Samuel McLenachan; Optical coherence tomography derived macular volume loss over 5 years in Stargardt disease. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4521. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine the variability in the rate of macular volume loss (MVL) in Stargardt disease derived from spectral domain-optical coherence tomography (SD-OCT).

Methods : Subjects with clinical Stargardt disease and biphasic ABCA4 mutations were eligible. Assessments included ETDRS visual acuity, fundus examination, widefield fundus autofluorescence (FAF, Optos) and SD-OCT (30°×25°, 61 slices with 119µm separation, Heidelberg Spectralis OCT) imaging. FAF pattern was divided into types A and B, defined by lesions confined to within or extended beyond the central 50°, respectively. Manual centration of the ETDRS grid and correction of segmentation errors in the inner limiting and Bruch’s membranes were performed. Patients with choroidal neovascular membrane, severe epiretinal membrane and decentred scans leading to image truncation within the ETDRS grid boundary were excluded. Annualised MVL was calculated by linear regression after confirming the rate of decline was constant. Inter-ocular (OD-OS) and inter-individual variabilities (OD only) in baseline total macular volume (TMV) and annualised MVL were explored.

Results : Forty eyes of 20 patients (mean age 39 years, mean symptom duration 13 years) were recruited and followed for a mean (SD) of 5.0 (1.0) years (range: 3.5-6.6 years). Five patients had late-onset disease (defined as symptom onset >40yrs) and 8 had a Type A FAF pattern. Mean (SD, range) number of OCT scanning sessions was 7.3 (2.1, 4-12) during follow up. Inter-ocular differences and agreements (bias, SD, 95% CI) in TMV (mm3) and MVL (mm3/year) were +0.03, 0.31, -0.12 to +0.18 and +0.02, 0.10, -0.03 to +0.06, respectively. Baseline TMV (OD) was negatively correlated with duration of symptoms (Pearson correlation, r = -0.76, p < 0.001) and associated with FAF pattern (7.55 vs 6.01 mm3, A vs B, p = 0.01). In contrast, there was no significant relationship between MVL (OD) and duration of symptoms or FAF patterns. A trend for lower rates of MVL in those with longer symptom duration (r = 0.27, p = 0.25) and FAF pattern A (mean (SD): -0.09 (0.07) vs -0.16 (0.12) mm3/year, p = 0.16, respectively) were noted.

Conclusions : MVL in Stargardt disease requires extensive and time-consuming manual correction of segmentation errors. Duration of symptoms and FAF patterns are associated with baseline TMV but not with MVL. These estimates in MVL can be used for sample size calculation in clinical trials.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×